Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
NL0011832936
Thu, 30.03.2023       Cosmo Pharmaceuticals N.V.
NL0011832936

Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings 30.03.2023 / 06:00 GMT/BST Dublin, Ireland – March 30, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the territory expansio [ … ]
Technical analysis
To the publication
Thu, 30.03.2023       Cosmo Pharmaceuticals N.V.
NL0011832936

Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings 30.03.2023 / 06:00 GMT/BST Dublin, Ireland – March 30, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the territory expansio [ … ]
Technical analysis
To the publication
Thu, 23.03.2023       Cosmo Pharmaceuticals N.V.
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR   Dublin, Ireland – 23 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) reports full-year 2022 financial results for the year ended 31 December 2022.   Financial highlights   In 2022, Cosmo has overtaken the €100 million annual revenue threshold for the first time. Revenues € [ … ]
Technical analysis
To the publication
Thu, 23.03.2023       Cosmo Pharmaceuticals N.V.
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR   Dublin, Ireland – 23 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) reports full-year 2022 financial results for the year ended 31 December 2022.   Financial highlights   In 2022, Cosmo has overtaken the €100 million annual revenue threshold for the first time. Revenues € [ … ]
Technical analysis
To the publication
Wed, 22.03.2023       Cosmo Pharmaceuticals N.V.
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 22 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its fully owned subsidiary Cosmo Intelligent Medical Devices – IMD is expanding its cooperation with Medtronic, the world’s largest healthcare technology provider, to accelerate the developme [ … ]
Technical analysis
To the publication
Wed, 22.03.2023       Cosmo Pharmaceuticals N.V.
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 22 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its fully owned subsidiary Cosmo Intelligent Medical Devices – IMD is expanding its cooperation with Medtronic, the world’s largest healthcare technology provider, to accelerate the developme [ … ]
Technical analysis
To the publication
Thu, 16.03.2023       Cosmo Pharmaceuticals N.V.
NL0011832936

Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023 16.03.2023 / 06:00 GMT/BST Dublin, Ireland – 16 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its  [ … ]
Technical analysis
To the publication
Thu, 16.03.2023       Cosmo Pharmaceuticals N.V.
NL0011832936

Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023 16.03.2023 / 06:00 GMT/BST Dublin, Ireland – 16 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its  [ … ]
Technical analysis
To the publication
Thu, 16.02.2023       Cosmo Pharmaceuticals N.V.
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 16 February 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced its preliminary unaudited results for the financial year 2022. Total revenues of €102.1m vs. guidance of €90m - €100m, representing growth of 56.9% compared to 2021 (€ 65.1m) Operating profit [ … ]
Technical analysis
To the publication
Thu, 16.02.2023       Cosmo Pharmaceuticals N.V.
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 16 February 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced its preliminary unaudited results for the financial year 2022. Total revenues of €102.1m vs. guidance of €90m - €100m, representing growth of 56.9% compared to 2021 (€ 65.1m) Operating profit [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 06.10.2024, Calendar Week 40, 280th day of the year, 86 days remaining until EoY.